Giovanni Crisafulli
YOU?
Author Swipe
View article: Clinical Actionability of Genes in Gastrointestinal Tumors
Clinical Actionability of Genes in Gastrointestinal Tumors Open
Precision oncology is witnessing an increasing number of molecular targets fueled by the continuous improvement of cancer genomics and drug development. Tumor genomic profiling is nowadays (August 2025) part of routine cancer patient care,…
View article: Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like Features
Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like Features Open
The incidence of early-onset colorectal cancer (EO-CRC, diagnosed earlier than age 50) is rising worldwide. Despite distinctive clinicopathological features, whether EO-CRC represents a biologically distinct entity from standard-onset CRC …
View article: Correction: Preoperative ctDNA retains prognostic relevance beyond postoperative assessment in stage II–III colon cancer
Correction: Preoperative ctDNA retains prognostic relevance beyond postoperative assessment in stage II–III colon cancer Open
View article: 82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer
82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer Open
View article: Preoperative ctDNA retains prognostic relevance beyond postoperative assessment in stage II–III colon cancer
Preoperative ctDNA retains prognostic relevance beyond postoperative assessment in stage II–III colon cancer Open
In cancer patients, only a small fraction of circulating cell-free DNA (cfDNA) consists of circulating tumor DNA (ctDNA), which contains tumor-specific features. Detecting ctDNA in peripheral blood through liquid biopsy offers a safe, noni…
View article: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models Open
View article: Clinical utility and future perspectives of liquid biopsy in colorectal cancer
Clinical utility and future perspectives of liquid biopsy in colorectal cancer Open
Liquid biopsy analyses of circulating tumor DNA are emerging as transformative tools for colorectal cancer management, enabling disease detection, monitoring, and treatment. Here, we critically assess its evidence-based utility in current …
View article: Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment Open
This review provides a comprehensive overview of the evolving role of minimal residual disease (MRD) for patients with Colon Cancer (CC). Currently, the standard of care for patients with non-metastatic CC is adjuvant chemotherapy (ACT) fo…
View article: DNA demethylation triggers cell free DNA release in colorectal cancer cells
DNA demethylation triggers cell free DNA release in colorectal cancer cells Open
Background Liquid biopsy based on cell-free DNA (cfDNA) analysis holds significant promise as a minimally invasive approach for the diagnosis, genotyping, and monitoring of solid malignancies. Human tumors release cfDNA in the bloodstream …
View article: Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer Open
This work was supported by the H2020 European ERA-NET grant on Translational Cancer Research (TRANSCAN-2).
View article: Mutational Signatures in Colorectal Cancer: Translational Insights, Clinical Applications, and Limitations
Mutational Signatures in Colorectal Cancer: Translational Insights, Clinical Applications, and Limitations Open
A multitude of exogenous and endogenous processes have the potential to result in DNA damage. While the repair mechanisms are typically capable of correcting this damage, errors in the repair process can result in mutations. The findings o…
View article: Mutational signatures of colorectal cancers according to distinct computational workflows
Mutational signatures of colorectal cancers according to distinct computational workflows Open
Tumor mutational signatures have gained prominence in cancer research, yet the lack of standardized methods hinders reproducibility and robustness. Leveraging colorectal cancer (CRC) as a model, we explored the influence of computational p…
View article: Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer Open
Multiple strategies are continuously being explored to expand the drug target repertoire in solid tumors. We devised a novel computational workflow for transcriptome‐wide gene expression outlier analysis that allows the systematic identifi…
View article: Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance Open
EDITORIAL article Front. Oncol., 08 August 2023Sec. Gastrointestinal Cancers: Colorectal Cancer Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1260158
View article: Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas
Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas Open
Glioblastoma (GBM) is known as an intractable, highly heterogeneous tumor encompassing multiple subclones, each supported by a distinct glioblastoma stem cell (GSC). The contribution of GSC genetic and transcriptional heterogeneity to tumo…
View article: Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer Open
In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number of actionable tar…
View article: Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade. We previously reported that the t…
View article: Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
View article: Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
View article: Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade. We previously reported that the t…
View article: Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Supplementary Figure 4 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy Open
Supplementary Figure 4
View article: Cell Model Network-UK from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Cell Model Network-UK from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy Open
The Cell Model Network-UK group author list
View article: Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
SNP ID.
View article: Data from Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Data from Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer Open
How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrate…
View article: Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Data from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy Open
Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer. The clinical effectiveness of targeted therapy and chemotherapy…
View article: Supplementary Figure 2 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Supplementary Figure 2 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy Open
Supplementary Figure 2
View article: Data from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Data from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
Purpose:Current glioma diagnostic guidelines call for molecular profiling to stratify patients into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, cerebrospinal fluid (CSF) has been proposed as a reliable tum…
View article: Data from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Data from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer Open
Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement displayed a…
View article: Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy
Supplementary Figure 5 from Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy Open
Supplementary Figure 5
View article: Supplementary Figures S1 - S3, Tables S1 - S6 from Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Supplementary Figures S1 - S3, Tables S1 - S6 from Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer Open
Supplementary Figure S1. MEK1 K57 mutation confers resistance to anti-EGFR antibodies in CRC preclinical models. Supplementary Figure S2. Dual blockade of EGFR and MEK restores sensitivity to CRC cells expressing MEK1 K57N or K57T. Supplem…